Norgine Appoints Janneke van der Kamp As The New CEO

Norgine, a prominent specialty pharmaceutical company in Europe, has officially named Janneke van der Kamp as its new Chief Executive Officer (CEO), starting 1 January 2025. Chris Bath, the current CEO, has resigned from his position, effective immediately. This leadership transition aims to bolster Norgine's mission of delivering transformative medicines to patients and consumers while maintaining its robust growth trajectory. The company will focus on enhancing existing brands, developing and commercializing new products, and expanding its business development efforts.

Janneke van der Kamp comes to Norgine with over 20 years of experience in the pharmaceutical sector. She previously served as Chief Commercial Officer at Grünenthal and held various significant roles at Novartis, including Head of Pharma Region Europe, General Manager, and Global Head of Neurosciences. She holds an M.Sc in Chemistry and an MBA from INSEAD. Following the investment from Goldman Sachs Alternatives in 2022, Norgine's senior leadership team has been strengthened to support the company's ambitious growth and transformation goals. The leadership team will continue to drive the business forward, with full backing from the Board.

Peter Stein, Chairman of Norgine said in a statement, “On behalf of the Norgine Board of Directors and shareholders, we are excited to welcome Janneke to lead Norgine. She is a world class and proven strategic leader with extensive experience in the pharmaceutical industry, leading organisations and launching innovative products to transform patient outcomes. With Janneke’s appointment, we have attracted the ideal leader for the next phase of Norgine’s exciting growth. Janneke brings to Norgine a deep understanding of the industry, unmatched energy and passion for improving patients’ and consumers’ lives and a commitment to creating value for shareholders, customers and colleagues.”

Janneke van der Kamp, incoming CEO of Norgine, mentioned “I am honoured and excited to serve as the next CEO of Norgine.  This is an outstanding business, with a great heritage and exciting future.  What excites me most is the opportunity to drive the next growth phase at Norgine, with our market leading launch and growth of Rx brands, the tremendous Movicol consumer health franchise, and our ambitious plans to accelerate licensing and acquisitions of innovative medicines. I look forward to connecting with our patients, customers, partners and, most of all, my new colleagues across Europe and ANZ.”